EPAM Systems (EPAM) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
19 Feb, 2026Executive summary
Achieved strong Q4 and full-year 2025 results, with double-digit revenue growth and outperformance versus guidance, driven by AI-native and AI foundational services momentum.
AI-native revenues exceeded $105 million in Q4, with expectations to surpass $600 million in 2026, reflecting rapid scaling and robust demand.
Recognized as a leader in generative AI consulting and implementation by Gartner, and received multiple industry awards for innovation and service quality.
Full year GAAP diluted EPS was $6.72 (down 14.3% YoY); non-GAAP diluted EPS was $11.50 (up 5.9% YoY).
Strong growth in AI-native revenues and continued investment in AI innovation and talent.
Financial highlights
Q4 2025 revenue was $1.408 billion, up 12.8% year-over-year; full-year 2025 revenue reached $5.457 billion, up 15.4% year-over-year.
Q4 GAAP income from operations was $149.3 million (10.6% margin); non-GAAP was $230 million (16.3% margin).
Full year GAAP income from operations was $520 million (9.5% margin); non-GAAP was $831.5 million (15.2% margin).
Q4 GAAP EPS was $1.98; non-GAAP EPS was $3.26, up 14.8% year-over-year.
Free cash flow in Q4 was $268 million, and $613 million for the full year, with a 94.7% adjusted net income conversion.
Outlook and guidance
2026 revenue growth expected at 4.5%-7.5% reported, with 3%-6% organic constant currency growth.
GAAP operating margin guidance: 10%-11%; non-GAAP: 15%-16%.
2026 GAAP EPS expected at $7.95-$8.25; non-GAAP EPS at $12.60-$12.90, up 10.9% YoY.
Q1 2026 revenue guidance: $1.385-$1.4 billion, with 3% organic constant currency growth at midpoint; non-GAAP EPS $2.70–$2.78, up 13.7% YoY.
Guidance reflects a -1% headwind from a large NEORIS client and assumes stable productivity in Ukraine.
Latest events from EPAM Systems
- Accelerating as an AI-native leader, targeting 16%+ margins and $1.8B+ free cash flow by 2028.EPAM
Investor Day 202612 Mar 2026 - Q2 revenue down 2% YoY; healthcare strong, margins lower, new $500M buyback approved.EPAM
Q2 20242 Feb 2026 - Q3 revenue and EPS rose, NEORIS acquisition expanded reach, and share buybacks accelerated.EPAM
Q3 202416 Jan 2026 - Q4 2024 delivered strong growth and 2025 guidance targets double-digit revenue gains.EPAM
Q4 202413 Dec 2025 - Board declassification, majority voting, and new incentive plan headline 2025 proxy.EPAM
Proxy Filing1 Dec 2025 - Proxy seeks approval for board declassification, majority voting, and new long-term incentive plan.EPAM
Proxy Filing1 Dec 2025 - Key votes include director elections, governance reforms, and executive pay approval.EPAM
Proxy Filing1 Dec 2025 - Leadership transition announced: Dobkin to Executive Chairman, Fejes to CEO in September 2025.EPAM
Proxy Filing1 Dec 2025 - Q2 revenue up 18% year-over-year; full-year outlook raised, margins pressured by higher costs.EPAM
Q2 202523 Nov 2025